HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.

Abstract
The efficacy of hydroxyurea (HU) in myeloproliferative disorders is well documented. HU controls thrombocytosis both in polycythemia vera (PV) and in essential thrombocythemia (ET), while reducing the risk of thrombosis.1 Despite many anectodal reports, no evaluation of the prevalence and type of side effects of HU exists in large series of patients.
AuthorsMaria Luigia Randi, Elisabetta Ruzzon, Guido Luzzatto, Fabiana Tezza, Antonio Girolami, Fabrizio Fabris
JournalHaematologica (Haematologica) Vol. 90 Issue 2 Pg. 261-2 (Feb 2005) ISSN: 1592-8721 [Electronic] Italy
PMID15710584 (Publication Type: Letter)
Chemical References
  • Enzyme Inhibitors
  • Busulfan
  • Hydroxyurea
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Busulfan (pharmacology)
  • Enzyme Inhibitors (pharmacology)
  • Female
  • Humans
  • Hydroxyurea (adverse effects, pharmacology)
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (genetics, metabolism)
  • Male
  • Middle Aged
  • Myeloproliferative Disorders (drug therapy)
  • Polycythemia Vera (drug therapy)
  • Retrospective Studies
  • Thrombocytosis (drug therapy)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: